Implementation considerations for multisite clinical trials with cognitive neuroscience tasks

被引:16
|
作者
Keefe, Richard S. E. [1 ]
Harvey, Philip D. [2 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA
[2] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA
关键词
schizophrenia; clinical trials; cognition;
D O I
10.1093/schbul/sbn042
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Multisite clinical trials aimed at cognitive enhancement across various neuropsychiatric conditions have employed standard neuropsychological tests as outcome measures. While these tests have enjoyed wide clinical use and have proven reliable and predictive of functional disability, a number of implementation challenges have arisen when these tests are used in clinical trials. These issues are likely to be magnified in future studies when cognitive neuroscience (CN) procedures are explored in these trials, because in their current forms CN procedures are less standardized and more difficult to teach and monitor. For multisite trials, we anticipate that the most challenging issues will include assuring tester competence, monitoring tester performance, specific challenges with complex assessment methods, and having resources available for adequate monitoring of data quality. Suggestions for overcoming these implementation challenges are offered.
引用
收藏
页码:656 / 663
页数:8
相关论文
共 50 条
  • [1] Considerations in the Design of Clinical Trials for Cognitive Aging
    Reiman, Eric M.
    Brinton, Roberta Diaz
    Katz, Russell
    Petersen, Ronald C.
    Negash, Selam
    Mungas, Dan
    Aisen, Paul S.
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2012, 67 (07): : 766 - 772
  • [2] Ethical considerations in clinical neuroscience - Current concepts in neuroclinical trials
    Alves, WA
    Macciocchi, SN
    STROKE, 1996, 27 (10) : 1903 - 1909
  • [3] Going From Social Neuroscience to Schizophrenia Clinical Trials
    Green, Michael F.
    Penn, David L.
    SCHIZOPHRENIA BULLETIN, 2013, 39 (06) : 1189 - 1191
  • [4] Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology
    Cerhan, Jane H.
    Anderson, S. Keith
    Butts, Alissa M.
    Porter, Alyx B.
    Jaeckle, Kurt
    Galanis, Evanthia
    Brown, Paul D.
    NEURO-ONCOLOGY PRACTICE, 2019, 6 (04) : 283 - 288
  • [5] Assessing cognitive function in clinical trials of schizophrenia
    Barnett, Jennifer H.
    Robbins, Trevor W.
    Leeson, Verity C.
    Sahakian, Barbara J.
    Joyce, Eileen M.
    Blackwell, Andrew D.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2010, 34 (08) : 1161 - 1177
  • [6] Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications
    Green, MF
    Braff, DL
    BIOLOGICAL PSYCHIATRY, 2001, 49 (04) : 374 - 384
  • [7] Strategies to encourage adoption in multisite clinical trials
    Guydish, Joseph
    Tajima, Barbara
    Manser, Sarah Turcotte
    Jessup, Martha
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2007, 32 (02) : 177 - 188
  • [8] The problem of measurement error in multisite clinical trials
    Demitrack, MA
    Faries, D
    Herrera, JM
    DeBrota, DJ
    Potter, WZ
    PSYCHOPHARMACOLOGY BULLETIN, 1998, 34 (01) : 19 - 24
  • [9] Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials
    Sarah K. Lageman
    Jane H. Cerhan
    Dona E. C. Locke
    S. Keith Anderson
    Wenting Wu
    Paul D. Brown
    Journal of Neuro-Oncology, 2010, 96 : 271 - 276
  • [10] Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials
    Lageman, Sarah K.
    Cerhan, Jane H.
    Locke, Dona E. C.
    Anderson, S. Keith
    Wu, Wenting
    Brown, Paul D.
    JOURNAL OF NEURO-ONCOLOGY, 2010, 96 (02) : 271 - 276